Disulfiram as a Modulator of Amyloid Precursor Protein-processing

NCT ID: NCT03212599

Last Updated: 2017-07-24

Basic Information

• Recruitment Status: COMPLETED
• Total Enrollment: 17 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2013-05-31
• Study Completion Date: 2017-07-31

Brief Summary

A causal therapeutic approach for treatment of Alzheimer's disease has not been established so far. The protein ADAM10 represents a promising target for an A-beta peptide preventing strategy. Treatment of human neuronal cells with Disulfiram, a drug which is used in clinical routine for recrudescence prevention of alcohol dependency, revealed an increased expression of ADAM10. This finding indicates a neuroprotective potential of Disulfiram. The investigators' research purpose aims at the verification of the results obtained in cell culture experiments in the human organism. Therefore, include alcohol addicted patients were included, which take the drug Disulfiram for recrudescence prevention, in our study. Patients are recruited from the patient-collective of the University Medical Center Mainz and the Central Institute for Mental Health Mannheim. Blood samples (max. 5 ml) are taken from the participants before the intake of Disulfiram and about two weeks after treatment. Demographic data are collected (such as age or onset of addiction). Gene expression is analyzed via reverse transcription polymerase chain reaction(RT-PCR) from blood cell-derived messenger ribonucleic acid (mRNA).

Conditions

Alcohol Addiction

Study Design

• Observational Model Type: CASE_CONTROL
• Study Time Perspective: PROSPECTIVE

Interventions

Disulfiram

alcohol addicted patients receive an oral Disulfiram application as recrudescence prevention after successful detoxication

Intervention Type: DRUG

Other Intervention Names

Antabus

Eligibility Criteria

Inclusion Criteria

ambulant or stationary patients, which receive Disulfiram for recrudescence prevention

Exclusion Criteria

Diagnosed Alzheimer's dementia Previous Disulfiram treatment less than four weeks before baseline blood collection

• Minimum Eligible Age: 20 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Johannes Gutenberg University Mainz

OTHER

Sponsor Role: lead

Responsible Party

K. Lieb

Director

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Kristina Endres

Role: PRINCIPAL_INVESTIGATOR

Medical Center Johannes Gutenberg University

References

Saifi MA, Shaikh AS, Kaki VR, Godugu C. Disulfiram prevents collagen crosslinking and inhibits renal fibrosis by inhibiting lysyl oxidase enzymes. J Cell Physiol. 2022 May;237(5):2516-2527. doi: 10.1002/jcp.30717. Epub 2022 Mar 13.

Reference Type: DERIVED

PMID: 35285015 (View on PubMed)

Other Identifiers

DIMAP

Identifier Type: -

Identifier Source: org_study_id